RxDoctor Payments Data

Haydn Thomas

Psychosomatic Medicine · Prairie Village, KSNPI 1669686465

Payments from drug & device makers

$4,001,968in general payments, 2019–2025

Across 874 payments — averaging $4578.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.6M
  • Biohaven Pharmaceuticals, Inc.$606K
  • Biohaven Pharmaceutical Holding Company Ltd.$516K
  • Pfizer$410K
  • H. Lundbeck A S$197K
  • Takeda Pharmaceuticals U.S.A., Inc.$135K
  • plus $500K from 14 others
$267,227in research payments, 2019–2025

Across 34 payments — averaging $7859.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$232K
  • Orexo US, Inc.$32K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Acadia Pharmaceuticals Inc$478

What the payments were for

  • Consulting fees$3,3007%
  • Speaking & faculty fees$30,35060%
  • Travel & lodging$14,29628%
  • Food & beverage$2,4505%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few psychosomatic medicine providers in Kansasto place this figure against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →